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CD4+ helper T cells are indispensible in shaping the
adaptive immune system and play an important role in
protection against infections. The establishment of a wide
range of long-lived pathogen-speciﬁc T cells, which are
ready-to-act upon second encounter with the speciﬁc path-
ogen, is a fundamental property of the adaptive immune
response. However, the mechanisms by which antigen
speciﬁc helper T are sustained long-term and resist insult by
lymphocytotoxic agents is not well deﬁned. A recent report
described the existence of a long-lived CD8+ memory T cell
population with stem cell-like properties (Turtle et al.,
Immunity 2009) including the ability to efﬂux cellular toxins
through the ATP-binding cassette (ABC)esuperfamily
multidrug efﬂux protein ABCB1. We hypothesized that
a subset of memory T cells with stem-like properties also
exists within the CD4+ T cell compartment.
Here we identiﬁed a subset of memory CD4+ T cells with
rapid drug-efﬂuxing ability. We showed that drug efﬂuxing
CD4+T cells have a remarkable phenotypic similarity to CD8+
stem-like memory T cells described by Turtle et al and are
deﬁned as CD161+CD95+CD45RA-CD127hiCD28+CD25int.
Furthermore, efﬂuxing CD4+CD161+ T cells proliferated
poorly in response to anti-CD3/CD28 stimulation compared
to their CD161- counterpart, indicating that this subset of
quiescent T cells may resist insult by cytotoxic agents
through a number of different mechanisms.
We demonstrated that CD4+CD161+ T cells are enriched
within the viral-speciﬁc T cell repertoire and persist after
chemotherapy for AML. The high ABCB1-mediated drug
efﬂux capacity of CD4+ CD161+ memory cells facilitated their
resistance to daunorubicin in vitro and, this resistance was
abrogated by the addition of competitive inhibitors of ABCB1
and ABCC1. Finally we demonstrated that following vacci-
nation with seasonal inﬂuenza vaccine (Flu), CD161 expres-
sion was signiﬁcantly higher on Flu-speciﬁc CD4+ T cells at 2
years, compared to 4 weeks post-vaccination, (74.3%  4.6%
vs. 49.3%  3.5% P  .007), suggesting that CD161 is a marker
for long-lived Ag speciﬁc memory T cells. These data have
signiﬁcant implications for the development of novel adop-
tive therapy strategies using long-lived stem-like memory T
cells.
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Autologous stem cell transplantation (auto-SCT) is
uncommonly associated with acute graft-versus-host
disease (aGVHD)-like syndromes that are typically mild and
self-limited; incidence is increased when auto-SCT is
coupled with infusion of ex vivo expanded/costimulated T-
cells. We describe here a gastrointestinal GVHD-like
syndrome in multiple myeloma (MM) patients treated with
auto-SCT and T-regulatory-cell (Treg)-depleted, autologous T-
cells genetically modiﬁed to express a T-cell receptor with
engineered speciﬁcity for a HLA-A*02-restricted epitope
common to cancer-testis antigens NY-ESO-1 and LAGE-1.
Subjects were HLA-A2+ and had high-risk MM with
conﬁrmed target expression. After initial therapy, T-cells
were harvested via apheresis for transduction and culture
with anti-CD3/-CD28-antibody-conjugated microbeads.
Stem cells were then mobilized with cyclophosphamide +/-
bortezomib. Subjects received melphalan 200 mg/m2 on day
-2 and >2 x 106 CD34+ cells/kg on day 0. On day +2, autol-
ogous T-cells were infused (avg. 9x109, range 7-10x109;
gene-modiﬁed avg. 33%, range 18-38%). Of the ﬁrst 3 subjects
treated, all developed persistent fever and grade 3-4 diarrhea
beginning between days 2-7. Abdominal imaging was ob-
tained in 2 subjects and demonstrated marked wall thick-
ening in the small and large bowel. Bowel biopsies from all
subjects demonstrated aGVHD. The syndrome resolved
spontaneously on day +37 in subject #1, but subjects #2 and
#3 required immunosuppression with steroids. With recog-
nition of this syndrome, prophylactic administration of oral
budesonide and beclomethasone was implemented. The
syndrome was then observed in only 1 of 7 subsequently
treated subjects; in this subject, symptoms developed only
after prophylactic budesonide was discontinued due to
inability to administer the drug while the subject was
ventilator-dependent with pneumonia. In subjects #2 and
#3, bowel biopsy specimens were assayed by qPCR for the
presence of the engineered cells, which were found to be
present in all biopsy specimens fromboth subjects. Q-RT-PCR
analysis of biopsy tissues showed absence of transcripts for
both NY-ESO-1 and LAGE-1 antigens and accumulation. In
conclusion, immunotherapy with Treg-depleted, NY-ESO-1/
LAGE-directed autologous T-cells after high-dose melphalan
is associated with a steroid-responsive and preventable
immune enteritis possibly mediated by inﬁltration of the GI
tract by the engineered autologous T-cells.46
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CMV infections cause signiﬁcant morbidity & mortality,
particularly among HLA mismatched HSCT recipients.
Adoptive immunotherapy using donor derived CMV-Speciﬁc
cytotoxic T-cells (D-CMV-CTLs) can treat CMV infection in
such patients. However, D-CMV-CTLs cannot be generated
for HSCT recipients from CMV seronegative donors, and
generation of such T-cells (TC) from cord blood has been
difﬁcult. Furthermore, D-CMV-CTLs in recipients of HLA
disparate HSCT maybe ineffective if the HLA allele restricting
their cytotoxic activity is not shared between the donor and
host. In these conditions, persistent CMV reactivation can be
treated using pre-generated CMV-CTLs of deﬁned epitope
speciﬁcity and HLA restriction from third party donors.
Many HLA antigens (ags) have multiple allelic variants.
We asked if TC speciﬁc for epitopes of CMVpp65 presented
by one allelic variant might also recognize the same epitope
presented by other variants of the same HLA ag. We char-
acterized the epitope speciﬁcities and HLA restrictions of 105
CMV-CTLs generated and banked for a phase I clinical trial,
plus 41 additional donors. CMV-CTLs in 37 HLA A0201+
donors were consistently responsive to the A0201 presented
NLV epitope. These NLV responsive TC from HLA
A0201+donors were also cytotoxic against NLV loaded targets
expressing HLA A0201, 0205 and 0206, but not HLA 0202,
0211 and 0220. In 13 donors expressing HLA B40, B44 and
B42 ag, CMV-CTLs were responsive to the HERNGFTVL
epitope when presented by APCs expressing any one of the
following alleles: HLA B 4001, 4002, 4006, 4401, 4403 or
4202. Importantly, CTLs from any one of these donors were
also cytotoxic against HERNGFTVL loaded targets bearing
one each of these alleles. TC from 9 donors inheriting HLA
B35, all elicited responses to the epitope EVQAIRETVE which
could be presented by either HLA B3501, 3502, 3503, 3508 or
3511; each CTL line was also cytotoxic against EVQAIRETVE
loaded targets bearing one of these HLA B35 alleles. Similar
cross reactivity was demonstrated for the QYDPVAALF
epitope which can be recognized when presented by HLA
A2402, 2404 and A2407. In contrast, allelic variants for
a given HLA class-II allele do not share epitope speciﬁc
responses in all donors; e.g. T-cells responding to the
FTSQYRIQGKL are cytotoxic against peptide loaded DRB1
1101 targets, but do not lyse FTSQYRIQGKL loaded DRB11104
targets; DRB1 1104 presents a different epitope
VAALFFFDIDL.
Our ﬁndings indicate that certain immunodominant viral
epitopes may be presented by multiple allelic variants of
class-I HLA ags. These data suggest that HLA class-I restricted
epitope speciﬁc CMV-CTLs fromHLA disparate donors can be
effective in recipients sharing certain allelic variants within
the same class-I family. Thus, generation of a bank of CTLs
responding to common immunodominant epitopes could
also potentially be used for treatment of a broader patient
population at risk for CMV.47
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Background: Conventional steroid treatment for graft versus
host disease (GvHD) is effective for a limited number of
patients (pts). The use of mesenchymal stromal cells (MSC)
as second line of treatment has been reported with prom-
ising results. We assessed the safety and efﬁcacy of MSC, in
a prospective, multicenter, phase I study (EudraCT 2008-
007869-23) for the treatment of steroid resistant grade II-IV
GvHD.
Methods:MSCwere obtained from bone marrow harvests of
third party donors and expanded with platelet lysate.
Primary endpoint of the study was safety. Secondary
endpoints were response to MSC, overall survival (OS) and
transplant-related mortality (TRM). Plasma levels of IL2Ral-
pha by ELISA were analyzed for enrolled pts.
Results: Between August 2009, and June 2012, 16 children
and 31 adults were treated. The median dose of infused MSC
was 1.5106 cells per kg. Enrolled pts presented with acute
GvHD in 37 cases, chronic overlap syndrome in 7, and chronic
classic GvHD in 3 cases. 15 pts had grade II GvHD, 23 grade III
and 9 grade IV, according to NIH criteria. In 17 cases GvHD
involved a single organ. Pts were treated with a median of 3
MSC infusions. No signiﬁcant side effects were registered. 30
patients (63.8%) showed a clinical response. 13 of them
(27.6%) had a complete response and 17 (36.1%) a partial
response to treatment. 22 over 30 responding pts did not
require further lines of immunosuppression after MSC infu-
sion. Response was more likely in pts exhibiting grade II
GvHD versus those with severer grading (87.5% vs. 51.6%, P ¼
.02) and in pts receiving MSC within 30 days from GvHD
onset (75.9% vs. 43.7%, P ¼ .05). Median follow up for this
cohort is 200 days (range 30-1066). Responders show
a signiﬁcant lower TRM (10.0% vs. 88.2%, P< .05) and a better
OS probability than non responders (23.3% vs. 88.2%, P< .05).
When comparing responders vs non-responders, IL2Ralpha
showed a statistically signiﬁcant difference in terms of fold
decrease (p¼0.027), corroborating clinical results. Similarly,
a signiﬁcant trend of fold decrease (p¼0.058) was observed
when comparing responder patients receivingMSCwithin or
after 30 days from GvHD onset, in line with clinical results.
Conclusions: This study conﬁrms that MSC may represent
a safe and effective treatment for patients with steroid-
refractory GVHD. Plasmatic markers may help in monitoring
of clinical response. We suggest to consider the use of MSC as
early as possible, after steroid failure.48
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